Xoft was a lot of current revenues. The CAD devision is expected to get some approvals abroad and here and become a real revenue grower. This is expected to bring in a couple hundred million of high margin software revenues. All from xoft will be forgiven when that starts happening late this year into next. Also expect more Xoft country approval inclufing China which rely less on insurance. This is a clear 1 year doubler if not more and trading in the teens.
Holland’s SoLayTec will ship four of its InPassion PECVD tooling to two Chinese Tier 1 manufacturers. One tool is for a new customer’s R&D line, while three will go to an existing customer for volume production.
I would not short the company but I agree with you after seeing the fall to the 80 cents range. I bought that time on the way up around a dollar and sold my 5,000 shares around two bucks soon after. I wish I would have held to the teens but the opportunity may once again arise. Wall Street punishes companies in Leap Frogs position and the cash holdings are more of a trap for value investors. Who knows what that will become a year from now. I've been on the sidelines for some time and am tempted to jump in around these prices but risk/reward be better at a higher price once management has done a better job at proving they are on the right track. Leap TV would never take any share from playstation but I would buy Leap Frog products on the playstation.
Does LF really not plan on rekindling growth until holiday 2017? The cash is an aberration only at the burn rate. The company has been battling the likes of Apple and we truly saw who is winning this last holiday. It's not going back but the company seems to think the same old thing will get them back by 2017. Leap Frog needs a complete restructuring to get them with the times and a move from hardware to software and education through others hardware. This will take at least a 1/2 cut in workforce now or later and many many million dollars of restructuring costs. They wont have the money if a wait and see attitude is taken.
Board of directors in public companies are not Rottweilers and Pinschers they are most often tiny lap dogs like Chiwawas and they are usually smiling.
Board of directors are usually friends and also in the pockets of the company.
Top five alone will take over 2.5 million of it along with non cash compensation
Mr. John Barbour 683.00K
Mr. Raymond L. Arthur 655.00K
Mr. Gregory B. Ahearn 654.00K
Mr. Kenneth A. Adams 233.00K
Mr. Michael J. Dodd 460.00K
Options granted and exercised but that has a net effect on the shareprice as it gifts a company to executives over time that often don't want it thus selling shares back to new share holders in the open market.
You have to love the public markets if you are an exec
Cash burn is over 100 million and if the rate continues cash could be around 25 million by next year this time. The company will be a buy only with a good restructuring plan later on in the year.
I bought my LeapTV on Amazon so maybe there was a bad batch which was recalled from the stores. I never see any Leap TVs at Target but I don't think its because they were sold out even though there are games.
The volume does not always work but if you reboot it is usually back- never happens on the other consoles. The pointer not very interactive but seems to work if you are a few inches away from the sensor.
Leap TV may be for the kids that were never allowed to play video games on other consoles. Once you have the comparison is pathetic. I guess the games are comparable to the leap pad games but I expected more when its thrown on a large TV.
Leap TV is utter garbage. Its way easier to put my 4 year old in front of a real computer. Glitches up the wazoo on the remotes and the games. Very user unfriendly. Imagine buying a system marketed to be child user friendly and not being able to figure things out yourself. I wonder if Leap Frog will address the problem or keep a bad product going. As a prior investor I bought the system and about 5 games. I should have returned everything but at least I increased LF sales by that much last quarter when I did own shares. There will be lots of returns from angry parents.
That is a very accurate statement and the reason ICAD wont stay around these prices for long. Xoft keeps on making the news for how great the results are without the knife.
"Now we have a non-surgical option to offer our patients that has an outstanding cure rate that gives excellent cosmetic results," says Dr. Marcy L. Street, M.D. the founder and medical director of Doctor's Approach.
Brachytherapy coding has had a history of coding and recoding but in the end it "remains a major treatment modality for many cancer types and is considered a most highly efficacious and economical method of treatment delivery."
Educate yourself by googling Brachytherapy-Coding-Now-and-Then
Here is a bit of a read from it
"In 1994, the Health Care Financing Administration (HCFA)-now the Centers for Medicare and Medicaid Services-banned the use of many procedure codes that urologists had been using to charge for prostate seed implants. This unfortunate decision ostensibly ended prostate brachytherapy. AMAC and Theragenics petitioned and appealed HCFA's decision, which resulted in guidance whereby the urologist would "share" the code 77778 using modifiers 26-62.
This new guidance allowed both the urologist and the radiation oncologist to receive 62.5 percent of the Medicare allowable reimbursement. Use of prostrate seed implants increased but not to pre-1994 levels due to the complexity of the new coding modifiers. In 1996, a new code was released specifically for the urologists, 55859, now 55875; however, it was the Medicare allowable reimbursement low.
Eventually, the Medicare allowable increased appropriately, standard procedures were implemented, and reliable manufacturers emerged. As a consequence, prostate seed implants grew exponentially with manufacturers struggling to keep pace with the demand. In 2002 when intensity-modulated radiation therapy was subsequently introduced, there was a decline in prostate brachytherapy again.
A further advancement in brachytherapy came with the introduction of high-dose rate remote afterloading (HDR), in which a temporary implant of a high-dose iridium 192 source is placed near the tumor site using needles and catheters. The HDR unit was mobile with a remote lead storage receptacle for ease of use. Nucletron Corp. pioneered the early use of HDR. This treatment form was limited, though, because specific procedure codes had
Use the logic on this as insurances want to save money.
The Xoft system saves patients a hospital visit and when needed it takes less treatments. Medicare can't get rid of brachytherapy but wants to pay less since hospital visits and double the treatments are no longer necessary. A new code will come from this. Xoft does what took a big machine in a hospital and does it better while fitting in a corner.
Elderly patients are going to keep on getting skin cancers while on blood thinning medication. iCAD will have a new code and keep growing that less than 1% penetration into the market. The Medicare issue was a hiccup and a buying opportunity. How fast will the stock go up when Xoft gets a new code somewhere in the middle.
Does Roth Capital have anything to do with the 100 million shelf offering? Seems to be a lot of kickback like upgrades for registration fees. Either way more money buys more time.
HYGS caught even one of the analysts off guard with the good news.
Elford noted, “While we have long been highlighting the potential for large contracts to act as a positive catalyst for the stock, this application and partner were never on our radar screen until now. The opportunity persists for other large contract announcements over the balance of the year in Power-to-Gas and Stationary Power.” Furthermore, “We understand that Alstom conducted a global technical competition, which included all of the major fuel cell companies.
Did not think things through past step three and is stretching to save his idea by going to other markets.
Fast charging will never work with today's grid and more investment in it does not make sense as solar panels and power storage becomes localized at an amazing rate. Elon Musk is going for the localized energy avenue. 7 fast charging cars would take the power of 7000 houses. Take that grid! Hydrogen is one of the answers and could be the main one.... many many years away.
If you were to charge a car in 12 minutes for a range of 500 km (310 miles), for example, you're probably using up electricity required to power 1,000 houses," Tanaka told a small group of reporters at the first test-drive event for the production version of the Mirai, the world's only mass-market fuel-cell car.
"That totally goes against the need to stabilize electricity use on the grid."
Canaccord Genuity analyst Sara Elford weighed in today with a few insights on Hydrogenics Corporation (USA) (NASDAQ:HYGS), following the announcement that the company has been awarded an exclusive 10-year agreement valued at over #$%$50 million to supply Alstom Transport with hydrogen fuel cell systems for Regional Commuter Trains in Europe.
Elford noted, “While we have long been highlighting the potential for large contracts to act as a positive catalyst for the stock, this application and partner were never on our radar screen until now. The opportunity persists for other large contract announcements over the balance of the year in Power-to-Gas and Stationary Power.” Furthermore, “We understand that Alstom conducted a global technical competition, which included all of the major fuel cell companies. The fact that Hydrogenics won this competition (exclusivity noted) once again provides strong validation of its technology platform. The fuel cell systems will be developed to meet European train compliance regulations.”
Bottom line: “We are not changing our forecast at this time, but once again visibility has improved and Hydrogenics has reconfirmed that it is a leader in this space, with multiple applications to drive significant long-term growth.”
The analyst reiterated a Buy rating on Hydrogenics shares with a price target of $19, which implies an upside of 66% from current levels.
HYGS is not considered a BLDP FCEL or a PLUG. Deals like today's make investors think. If Wall Street Agrees that HYGS is a comparable company it goes up to 30 bucks and has a similar market cap to the others and trades relative to their market caps from here.
New application with more to come as fuel cells make their way into common use. The market is all hype as you know. +30% on this news or down still substantially for the year with another revenue stream.
Every once in a while they get burnt. Hence +$30 hydrogenics which is not unreasonable with a comparative market cap to PLUG, BLDP, and FCEL. It would be nice to see a rise and a split to get the share count to something a larger institution would feel more comfortable investing in.